Kestra Medical Technologies, Ltd.

KMTSNASDAQHealthcare● Active

$20.26

+$0.86(+4.43%)

Market Cap$1.2B

P/E Ratio—

52W High$30

52W Low$13.25

Avg Volume358K

Open$19.59

Beta0.83

Free Cash Flow Financials Revenue

Kestra Medical Technologies, Ltd. (KMTS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

KMTS · free cash flow · updated Jun 8, 2026

Core FCF metrics

KMTS · FCF · TTM · margin & CAGR

Free cash flow was −$101.2M for FY2025 (fiscal year ending 2025-04-30), down 19.4% year-over-year The FCF margin was -169.2%.

FY2025 Free Cash Flow−$101.2M▼ -19.4% YoY

Trailing 12M (TTM)−$120.0Mtrailing 4 quarters sum

FCF Margin-169.2%−$101.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

KMTS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$77.6M(24M)−$101.2M▼ 19.4%-169.2%

FY2024−$72.2M(13M)−$84.7M▲ +0.4%-304.7%

FY2023−$69.6M(15M)−$85.1M▼ 181.5%—

FY2021−$29.9M(0M)−$30.2M▲ +1.0%—

FY2020−$30.3M(0M)−$30.5M——

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

KMTS · P/FCF · FCF yield · FCF per share

Kestra Medical Technologies, Ltd. (KMTS) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-04-30

Cash flow statement summary

KMTS · cash flow statement · operating / investing / financing

For FY2025, Kestra Medical Technologies, Ltd. generated −$77.6M in operating cash flow and spent 24M in capital expenditures, yielding −$101.2M in free cash flow.

Operating Activities

−$77.6M

Cash from core business operations

2025-04-30

Investing Activities

−$23.3M

CapEx, acquisitions & investments

2025-04-30

Financing Activities

+$330.3M

Buybacks, dividends & debt

2025-04-30

FCF FormulaOperating CF (−$77.6M) − |CapEx| (24M) = FCF (−$101.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

KMTS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Kestra Medical Technologies, Ltd.YOU

KMTS

−$101.2M-19.4%-169.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Kestra Medical Technologies, Ltd. (KMTS) reported free cash flow of −$101.2M for FY2025 (fiscal year ending 2025-04-30), down 19.4% year-over-year. The FCF margin was -169.2%.

Kestra Medical Technologies, Ltd. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 5 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

KMTS free cash flow · 8 questions

Kestra Medical Technologies, Ltd. free cash flow was −$101.2M for FY2025, down 19.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$120.0M.

KMTS free cash flowKMTS FCFKMTS FCF 2025KMTS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Kestra Medical Technologies, Ltd. · Kestra Medical Technologies, Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026